Adrian P Gee

List of Publications by Year
in descending order

73 papers	5,750 citations	172386 29 h-index	133188 59 g-index
73 all docs	73 docs citations	73 times ranked	7283 citing authors

#	Article	IF	Citations
1	Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study. Cytotherapy, 2022, 24, 691-698.	0.3	1
2	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	0.6	14
3	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood, 2021, 137, 2585-2597.	0.6	38
4	Comparative analysis of cell therapy infusion workflows at clinical sites. Cytotherapy, 2021, 23, 285-292.	0.3	5
5	A Phase <scp>II</scp> study of autologous mesenchymal stromal cells and câ€kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the <scp>CCTRN CONCERTâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 661-674.	2.9	89
6	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	0.8	30
7	The National Heart, Lung, and Blood Instituteâ€funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy. Clinical and Translational Science, 2021, 14, 2099-2110.	1.5	1
8	Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury. JACC: CardioOncology, 2021, 3, 428-440.	1.7	42
9	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	0.6	0
10	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy HeartÂFailure Patients. JACC: CardioOncology, 2020, 2, 581-595.	1.7	24
11	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications, 2020, 11, 3549.	5.8	103
12	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 2020, 38, 3794-3804.	0.8	235
13	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Science Translational Medicine, 2020, 12, .	5.8	25
14	Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2020, 8, 547653.	1.8	44
15	Abstract 14859: Mesenchymal Stem Cells Rescue Patient-Specific Cardiomyocyte Viability and Function Following Doxorubicin Injury via Microvesicle Mediated Mitochondrial Transfer to Recapitulate Human Clinical Trial Results. Circulation, 2020, 142, .	1.6	0
16	Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells, 2019, 37, 1481-1491.	1.4	35
17	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptorâ€“Expressing T Cells. Clinical Cancer Research, 2019, 25, 7340-7350.	3.2	32
18	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 2019, 3, 2057-2068.	2.5	27

#	Article	IF	Citations
19	â€œMiniâ€•bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Advances, 2019, 3, 2571-2580.	2.5	44
20	GMP CAR-T cell production. Best Practice and Research in Clinical Haematology, 2018, 31, 126-134.	0.7	49
21	Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Molecular Therapy, 2018, 26, 6-7.	3.7	12
22	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139.	0.8	137
23	Regulation of Regenerative Medicine Products. Advances in Experimental Medicine and Biology, 2018, 1098, 189-198.	0.8	5
24	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361.	0.6	49
25	InÂVivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkinâ€™s Lymphomas. Molecular Therapy, 2018, 26, 2727-2737.	3.7	180
26	Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. American Heart Journal, 2018, 201, 54-62.	1.2	17
27	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). Blood, 2018, 132, 680-680.	0.6	20
28	HER2-Specific Chimeric Antigen Receptorâ€“Modified Virus-Specific T Cells for Progressive Glioblastoma. JAMA Oncology, 2017, 3, 1094.	3.4	608
29	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Molecular Therapy, 2017, 25, 2214-2224.	3.7	378
30	T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Molecular Therapy - Oncolytics, 2017, 6, 69-79.	2.0	26
31	Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants. Cytotherapy, 2017, 19, 36-46.	0.3	11
32	Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€“redirected lymphocytes. Journal of Clinical Investigation, 2017, 127, 3462-3471.	3.9	301
33	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3547-3557.	0.8	367
34	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. Journal of Clinical Oncology, 2017, 35, 10508-10508.	0.8	32
35	Abstract TP94: Mesenchymal Stromal Cells Behave Differently When Exposed to Medications Commonly Prescribed to Stroke Patients. Stroke, 2017, 48, .	1.0	0
36	Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods in Molecular Biology, 2016, 1441, 195-202.	0.4	20

#	Article	IF	Citations
37	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016, 18, 151-159.	0.3	400
38	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. Blood, 2016, 128, 1851-1851.	0.6	22
39	Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection. Blood, 2016, 128, 388-388.	0.6	1
40	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 501-501.	0.6	2
41	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015, 125, 4103-4113.	0.6	188
42	Human Epidermal Growth Factor Receptor 2 (HER2) â€“Specific Chimeric Antigen Receptorâ€“Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Journal of Clinical Oncology, 2015, 33, 1688-1696.	0.8	778
43	Quantitative activation suppression assay to evaluate human bone marrowâ€“derived mesenchymal stromal cell potency. Cytotherapy, 2015, 17, 1675-1686.	0.3	31
44	A reproducible immunopotency assay to measure mesenchymal stromal cellâ€“mediated T-cell suppression. Cytotherapy, 2015, 17, 140-151.	0.3	83
45	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. Journal of Clinical Oncology, 2015, 33, 3008-3008.	0.8	44
46	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	0.6	0
47	Optimizing the production of suspension cells using the G-Rex â€œMâ€•series. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14015.	1.8	71
48	Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine, 2014, 6, 242ra83.	5.8	357
49	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 2014, 32, 235-242.	1.2	21
50	CD34 measurement: setting standards. Cytotherapy, 2014, 16, 1451-1452.	0.3	0
51	Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy, 2014, 16, 1048-1058.	0.3	128
52	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood, 2014, 123, 3750-3759.	0.6	534
53	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target Îº-Light Immunoglobulin Chain. Blood, 2013, 122, 506-506.	0.6	6
54	Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	0.6	2

#	Article	IF	Citations
55	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 579-579.	0.6	2
56	Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 4643-4643.	0.8	2
57	Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order. Blood, 2012, 120, 1912-1912.	0.6	0
58	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2012, 120, 223-223.	0.6	25
59	Clinical-Scale Expansion of Human Bone Marrow-Derived Mesenchymal Stromal Cells to Treat Patients After Ischemic Stroke.. Blood, 2012, 120, 3021-3021.	0.6	0
60	Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. Blood, 2011, 118, 155-155.	0.6	4
61	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood, 2011, 118, 956-956.	0.6	1
62	Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy, 2010, 12, 684-691.	0.3	33
63	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	0.6	0
64	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	0.6	0
65	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	0.6	0
66	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505.	0.6	0
67	Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.. Blood, 2008, 112, 1968-1968.	0.6	0
68	Graft Composition and Outcomes in Unrelated Donor Transplantation.. Blood, 2007, 110, 3065-3065.	0.6	0
69	Flow Cytometric Analysis of Specimens by a Central Reference Laboratory in a Multi-Center Study: Factors Affecting Data Quality.. Blood, 2006, 108, 3385-3385.	0.6	1
70	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773.	0.6	0
71	Regulatory issues in cellular therapies. Expert Opinion on Biological Therapy, 2003, 3, 537-540.	1.4	5
72	The impact of regulatory policy on the development of somatic cell therapies in the United States. Transplant Immunology, 2002, 9, 295-300.	0.6	4

#	Article	IF	Citations
73	Regulatory issues in cellular therapies. Journal of Cellular Biochemistry, 2002, 85, 104-112.	1.2	4